
Quantum BioPharma's Lucid-MS Offers New Hope in Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which aims to repair myelin damage in multiple sclerosis, a progressive neurological disease affecting over 2.9 million people worldwide.
Read full story

























